» Articles » PMID: 28397762

Cellular Models and In Vitro Assays for the Screening of Modulators of P-gp, MRP1 and BCRP

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2017 Apr 12
PMID 28397762
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Adenosine triphosphate (ATP)-binding cassette (ABC) transporters are highly expressed in tumor cells, as well as in organs involved in absorption and secretion processes, mediating the ATP-dependent efflux of compounds, both endogenous substances and xenobiotics, including drugs. Their expression and activity levels are modulated by the presence of inhibitors, inducers and/or activators. In vitro, ex vivo and in vivo studies with both known and newly synthesized P-glycoprotein (P-gp) inducers and/or activators have shown the usefulness of these transport mechanisms in reducing the systemic exposure and specific tissue access of potentially harmful compounds. This article focuses on the main ABC transporters involved in multidrug resistance [P-gp, multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP)] expressed in tissues of toxicological relevance, such as the blood-brain barrier, cardiovascular system, liver, kidney and intestine. Moreover, it provides a review of the available cellular models, in vitro and ex vivo assays for the screening and selection of safe and specific inducers and activators of these membrane transporters. The available cellular models and in vitro assays have been proposed as high throughput and low-cost alternatives to excessive animal testing, allowing the evaluation of a large number of compounds.

Citing Articles

Blood-CSF barrier clearance of ABC transporter substrates is suppressed by interleukin-6 in lupus choroid plexus spheroids.

Reynolds J, Torz L, Cummins L, Stock A, Ben-Zvi A, Putterman C Fluids Barriers CNS. 2025; 22(1):15.

PMID: 39934822 PMC: 11816793. DOI: 10.1186/s12987-025-00628-x.


Utilizing surface plasmon resonance as a novel method for monitoring P-glycoprotein efflux.

Nguyen P, Cui S, Kozarich A, Rautio A, Roberts A, Xiong M Front Biophys. 2024; 2.

PMID: 38645731 PMC: 11027885. DOI: 10.3389/frbis.2024.1367511.


Phenylspirodrimane with Moderate Reversal Effect of Multidrug Resistance Isolated from the Deep-Sea Fungus sp. 3A00409.

Ma X, Wu M, Chen Z, Cao F, Zhong T, Luo Z Molecules. 2024; 29(7).

PMID: 38611964 PMC: 11013241. DOI: 10.3390/molecules29071685.


Co-Culture Models: Key Players in In Vitro Neurotoxicity, Neurodegeneration and BBB Modeling Studies.

Monteiro A, Barbosa D, Remiao F, Silva R Biomedicines. 2024; 12(3).

PMID: 38540242 PMC: 10967866. DOI: 10.3390/biomedicines12030626.


Consensus screening for a challenging target: the quest for P-glycoprotein inhibitors.

Governa P, Biagi M, Manetti F, Forli S RSC Med Chem. 2024; 15(2):720-732.

PMID: 38389870 PMC: 10880898. DOI: 10.1039/d3md00649b.


References
1.
Eilers M, Roy U, Mondal D . MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Exp Biol Med (Maywood). 2008; 233(9):1149-60. PMC: 2575034. DOI: 10.3181/0802-RM-59. View

2.
Westerlund M, Belin A, Anvret A, Hakansson A, Nissbrandt H, Lind C . Association of a polymorphism in the ABCB1 gene with Parkinson's disease. Parkinsonism Relat Disord. 2009; 15(6):422-4. DOI: 10.1016/j.parkreldis.2008.11.010. View

3.
Bansal T, Jaggi M, Khar R, Talegaonkar S . Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci. 2009; 12(1):46-78. DOI: 10.18433/j3rc77. View

4.
Sharom F . ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2007; 9(1):105-27. DOI: 10.2217/14622416.9.1.105. View

5.
Cheepala S, Hulot J, Morgan J, Sassi Y, Zhang W, Naren A . Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters. Annu Rev Pharmacol Toxicol. 2012; 53:231-53. PMC: 4303346. DOI: 10.1146/annurev-pharmtox-010611-134609. View